Dx & Vx Co., Ltd. (KOSDAQ:180400)

South Korea · Delayed Price · Currency is KRW

2,065.00

-10.00 (-0.48%)

At close: Nov 13, 2026

Market Cap	203.26B +100.5%
Revenue (ttm)	26.22B -15.7%
Net Income	-25.22B
EPS	-340.37
Shares Out	98.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,315
Open	2,085.00
Previous Close	2,075.00
Day's Range	1,950.00 - 2,135.00
52-Week Range	1,319.00 - 5,360.00
Beta	0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Mar 19, 2027

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2001

Employees 83

Stock Exchange KOSDAQ

Ticker Symbol 180400

Full Company Profile

Financial Performance

In 2025, Dx & Vx's revenue was 29.36 billion, a decrease of -13.52% compared to the previous year's 33.95 billion. Losses were -29.04 billion, -38.26% less than in 2024.

Financial Statements